期刊
JOURNAL OF CARDIOLOGY
卷 73, 期 1-2, 页码 102-107出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jjcc.2018.10.003
关键词
Vasopressin; Heart failure; Aquaporin
One of the vasopressin type 2 receptor antagonists, tolvaptan, has been used to treat congestive heart failure patients for over seven years in Japan. Beyond the initially suggested standard procedure, tolvaptan is currently used in patients with acute heart failure soon after their admission or it is used for long-term treatment in the ambulatory situation. Nevertheless, definitive evidence is lacking, particularly for the implication of long-term tolvaptan therapy. Now is the time to update the accumulating evidence and consider the optimal therapeutic strategy for short- and long-term tolvaptan therapy. (C) 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据